SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Simple laboratory based indices | Ray Kim, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Potential approach to identify the NAFLD patient who will develop HCC | Yujin Hoshida, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Lipid and Bile acids as NAFLD-related biomarkers | Puneet Puri, MBBS, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Study Design and endpoints in Omics-based biomarker studies | Stephen Williams, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Proteomics-based biomarker discovery in NAFLD | Naga Chalasani, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Biomarkers: what can be learned from type 2 diabetes | Manu Chakravarthy, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016O_02 - Performance of non-invasive tests in the staging of fibrosis in patients with NAFLD: interim results of a prospective multicentre study | Dr. P. EddowesView Slideset
ASArun SanyalMD, MBBSSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Defining the gold standard in Biomarker Validation in NAFLD | Arun Sanyal, MD, MBBSView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Quantitative measures of liver health | Grey Everson, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Principles of Biomarker Development | Margery Connelly, PhD, MBAView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016Need for Biomarker Development in Non-Alcoholic Fatty Liver Disease | Eric Lefebvre, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on NASH Biomarkers 2016O_06 - Longitudinal changes in FIB-4 and improvement in fibrosis stage with obeticholic acid: A secondary analysis of FLINT Trial | Dr. A. SanyalView Slideset
